Visakhapatnam, Jul 27 ()

(

) today bagged a Rs 102 crore contract from

for for dredging in the Pussur Channel.

The contract has been awarded by the

and involves dredging around 3.88 million cubic meters over the next 15 months, DCI said in a statement.

This is the first international contract bagged by DCI through an open global tender. DCI has planned to commence the dredging work by September. -----------------------------------------------------------

net jumps 86%

Mumbai:

player

today reported an 86 per cent rise in June quarter at Rs 16.9 crore.

New business premium doubled to Rs 298.1 crore from Rs 148.8 crore a year ago. Gross written premium grew 88 per cent at Rs 364.6 crore from Rs 194 crore a year ago.

Assets under management of the company increased 40 per cent to Rs 3,003.7 crore from Rs 2,145.7 crore a year ago.

"Achieving these results is a validation of our differentiated strategy that focuses on building segmented distribution channels, developing relevant and innovative products, and investment in technology and digital platforms to address the fast evolving customer need,"

, managing director and chief executive said. ------------------------------------------------------------ Harmony Hedge Fund to trade on MCX

Multi Commodity Exchange (MCX) today said Harmony Hedge Fund, a Category III alternative investment fund (AIF), began trading on its platform, becoming the first institutional participant to do so.

Institutional participation in commodity derivative markets has been awaited for the last 14 years since inception.

The decision comes after

on June 21 this year allowed Category III

to participate in the commodity derivatives market.

Mrugank Paranjape, MD & CEO of MCX said the entry of Harmony will spur the interest and participation of other AIFs too, whose collective presence will lend significant depth and vibrancy to India's commodity derivatives market". ------------------------------------------------------- Mylan

launches

for treatment HCV infection

Mylan Pharmaceuticals, a subsidiary of

today announced the launch of Velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults.

launched Velpatasvir 100 mg/Sofosbuvir 400 mg tablets under the brand name MyHep All in India. Its a fixed-dose combination tablet indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, including all six major HCV genotypes.

A Velpatasvir 100 mg /Sofosbuvir 400 mg combination product is currently sold by

in other markets under the brand name EPCLUSA. -------------------------------------------------------------- LinkedIn leads for pharma cos in digital engagement

LinkedIn followed by

and Twitter have emerged as the leading platforms for healthcare and pharmaceuticals companies in India for digital engagement according to the data revealed by D Yellow Elephant - a full-service digital & social media firm.

The report studied 160 India based companies across 4 verticals - pharmaceuticals, medical devices & equipment, diagnostics and hospitals on 12 key digital and social parameters - websites, apps, Facebook, Twitter, LinkedIn, YouTube , Google+, Blogger, Pinterest Instagram and Tumblr. COR KD BEN AP NRB